Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05117931 · ClinicalTrials.gov registry record · Phase 2
A Study of Amivantamab in People With Esophagogastric Cancer
A Phase 2 study of Esophagogastric Cancer, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 9
- Study locations
NCT05117931 is a Phase 2 study of Esophagogastric Cancer that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 25 participants, below the 78-participant average among 5 other Esophagogastric Cancer trials with a reported enrollment target (68% lower). The trial reports 9 study locations across 4 states.
The verdict
NCT05117931, a Phase 2 study of Esophagogastric Cancer, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 9
- Study locations
Study Summary
The purpose of this study is to see whether the study drug, amivantamab, is an effective treatment for people with EGFR- or MET-amplified esophagogastric cancer. The researchers will also look at whether amivantamab is a safe treatment that causes few or mild side effects in participants.
Conditions Studied
Interventions
- DRUG Amivantamab
Study Locations (9)
New York
- Memorial Sloan Kettering Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All Protocol Activities) - New York
- Memorial Sloan Kettering Nassau (Limited protocol activities) - Rockville Centre
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited protocol activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited protocol activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
California
- University of California, Irvine - Irvine
Massachusetts
- Massachusetts General Hospital (Data Collection Only) - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-12-02 |
| Est. Completion | 2026-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05117931
The ClinicalTrials.gov registry entry for NCT05117931 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 78-participant average among 5 other Esophagogastric Cancer trials with a reported enrollment target (68% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Esophagogastric Cancer appearing as the primary indexed condition, and to 1 intervention - of which Amivantamab is the first listed.
NCT05117931 reports 9 study locations spanning 4 distinct geographic areas - top geographies include New York, New Jersey, California.
Frequently Asked Questions
What is clinical trial NCT05117931 about?
NCT05117931 is a clinical study titled "A Study of Amivantamab in People With Esophagogastric Cancer". The purpose of this study is to see whether the study drug, amivantamab, is an effective treatment for people with EGFR- or MET-amplified esophagogastric cancer. The researchers will also look at whether amivantamab is a safe treatment that causes few or mild side effects in participants.
What is the current status of trial NCT05117931?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2021-12-02. Estimated completion is 2026-11.
What conditions does trial NCT05117931 study?
This clinical trial studies the following conditions: Esophagogastric Cancer.
What interventions are being tested in trial NCT05117931?
The interventions under investigation include: Amivantamab (DRUG).
Who is sponsoring clinical trial NCT05117931?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05117931 being conducted?
This trial has 9 study locations across California, Massachusetts, New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophagogastric Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Folfox+Irinotecan+Chemort In Esophageal Cancer
RECRUITING · Phase 2
-
A Study of Nivolumab Combined With FOLFOX and Regorafenib in People Who Have HER2-Negative Esophagogastric Cancer
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
ACTIVE NOT RECRUITING · Phase 1
-
A Trial of a New Type of Photodynamic Therapy (VTP) in the Treatment of Patients With Cancer of the Esophagus Who Have Trouble Swallowing
ACTIVE NOT RECRUITING · Phase 1
-
A Study of Tooth Erosion in People With Esophagogastric Cancer
ACTIVE NOT RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.